Cingulate Inc. (NASDAQ:CINGW) Sees Significant Growth in Short Interest

Cingulate Inc. (NASDAQ:CINGW) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 5,920 shares, a growth of 705.4% from the July 30th total of 735 shares. Based on an average daily volume of 44,420 shares, the short-interest ratio is presently 0.1 days.

Cingulate Price Performance

CINGW stock opened at $0.01 on Wednesday. Cingulate has a 12 month low of $0.00 and a 12 month high of $0.12. The firm has a 50 day simple moving average of $0.02 and a 200 day simple moving average of $0.03.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.